Table 3.

Risk of lymphoma associated to detection of antibodies to H. pylori

DiagnosisH. pylori positive/no. of subjects(%)OR* (95% CI)
Controls430/60371.3Reference
By histology:
All lymphomas367/53668.50.83 (0.64-1.08)
B-cell lymphoma307/43969.90.85 (0.65-1.12)
    Chronic lymphocytic leukemia82/11770.10.71 (0.45-1.12)
    Lymphoplasmocytic lymphoma15/2171.40.81 (0.30-2.19)
    Diffuse large B cell64/9368.80.97 (0.59-1.59)
    Plasma cell myeloma51/7468.90.78 (0.45-1.33)
    Marginal zone B cell17/2763.00.71 (0.31-1.62)
    Stomach MALT4/4100.0
    Splenic marginal zone lymphoma24/2692.33.97 (0.92-17.16)
    Follicular lymphoma28/3873.71.13 (0.52-2.47)
    Others B cell26/4360.50.62 (0.32-1.20)
Hodgkin lymphoma34/5858.60.82 (0.46-1.47)
T-cell lymphoma26/3966.70.72 (0.36-1.47)
    Mycosis fungoides13/1776.51.04 (0.33-3.30)
By site:
Nodal lymphomas313/45468.90.85 (0.65-1.12)
Extranodal lymphomas54/8265.90.73 (0.44-1.22)
    Stomach10/10100
  • * Adjusted for age, gender, and study center.